Is It Time To Reassess BeOne Medicines (ONC) After Recent Share Price Weakness

Simply Wall St.02:30

If you are wondering whether BeOne Medicines at around US$284.05 is giving you fair value or a potential mispricing, this article will walk through what the current market price might be saying about ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2619009120?lang=en_US&edition=fundamental","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","is_english":true,"pubTime":"2026-03-15 02:30","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2619009120","market":"nz","top_or_hot":-1,"title":"Is It Time To Reassess BeOne Medicines (ONC) After Recent Share Price Weakness","media":"Simply Wall St.","content":"<div>\n<p>If you are wondering whether BeOne Medicines at around US$284.05 is giving you fair value or a potential mispricing, this article will walk through what the current market price might be saying about ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-it-time-to-reassess-beone-medicines-onc-after-recent-shar\">Source Link</a>\n\n</div>\n","source":"simplywall_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Is It Time To Reassess BeOne Medicines (ONC) After Recent Share Price Weakness</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIs It Time To Reassess BeOne Medicines (ONC) After Recent Share Price Weakness\n</h2>\n\n<h4 class=\"meta\">\n\n\n2026-03-15 02:30 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-it-time-to-reassess-beone-medicines-onc-after-recent-shar><strong>Simply Wall St.</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>If you are wondering whether BeOne Medicines at around US$284.05 is giving you fair value or a potential mispricing, this article will walk through what the current market price might be saying about ...</p>\n\n<a href=\"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-it-time-to-reassess-beone-medicines-onc-after-recent-shar\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-it-time-to-reassess-beone-medicines-onc-after-recent-shar","article_id":"2619009120","we_media_id":null,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/us/pharmaceuticals-biotech/nasdaq-onc/beone-medicines/news/is-it-time-to-reassess-beone-medicines-onc-after-recent-shar","rn_cache_url":null,"directOrigin":true},"url":"https://stock-news.laohu8.com/highlight/detail?id=2619009120","pubTimestamp":1773513002,"columns":[],"sourceInfo":{"source_id":"simplywall_highlight","name":"Simply Wall St."},"weMediaInfo":null,"summary":"If you are wondering whether BeOne Medicines at around US$284.05 is giving you fair value or a potential mispricing, this article will walk through what the current market price might be saying about the business.\nThe stock has seen mixed returns, with a 5.7% decline over the last 7 days and a 19.1% decline over the last 30 days, set against a 27.2% return over 3 years and 9.6% over 1 year. These figures can change how investors view both its growth prospects and risk.\nRecent coverage of...","collect":0,"end_time":0,"defaultTopTitle":"simplywall.st","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","DCF":"Dreyfus Alcentra Global Credit Income 2024 Target Term Fund, Inc","MDCO":"麦迪逊医药","BK4526":"热门中概股","BK4588":"碎股","BK4585":"ETF&股票定投概念","ONC":"百济神州"},"translate_title":"近期股价疲软后，是时候重新评估BeOne Medicines(ONC)了吗","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MDCO":1.5,"ONC":1.5,"DCF":1},"content_text":"If you are wondering whether BeOne Medicines at around US$284.05 is giving you fair value or a potential mispricing, this article will walk through what the current market price might be saying about the business. The stock has seen mixed returns, with a 5.7% decline over the last 7 days and a 19.1% decline over the last 30 days, set against a 27.2% return over 3 years and 9.6% over 1 year. These figures can change how investors view both its growth prospects and risk. Recent coverage of BeOne Medicines has focused on its position in the pharmaceuticals and biotech space and how investors are reacting to sector wide sentiment. This helps frame these ups and downs in the share price. This context matters because sentiment around drug development pipelines, funding conditions and regulatory milestones often has a direct impact on how traders price companies like this. On our valuation checks, BeOne Medicines scores 3 out of 6, giving it a valuation score of 3. Next we will look at how different valuation approaches interpret that score while hinting at a more complete way to think about value later in the article.  Find out why BeOne Medicines's 9.6% return over the last year is lagging behind its peers. AdvertisementApproach 1: BeOne Medicines Discounted Cash Flow (DCF) Analysis A Discounted Cash Flow, or DCF, model looks at the cash BeOne Medicines is expected to generate in the future and then discounts those cash flows back to what they might be worth in today's dollars. For BeOne Medicines, the latest twelve month free cash flow is about $487.11 million. Based on analyst inputs for the next few years and then extrapolated estimates after that, Simply Wall St projects free cash flow reaching about $2,772.03 million in 2030 under a 2 Stage Free Cash Flow to Equity model. All cash flows are assessed in $ and then discounted using the DCF framework. When you total and discount these projected cash flows, the model arrives at an estimated intrinsic value of about $809.70 per share. Compared with the recent share price of around $284.05, the DCF output suggests the shares are trading at a 64.9% discount to this estimate. On this specific cash flow view, this indicates the stock may be undervalued according to the model's assumptions. Result: UNDERVALUED (MODEL-BASED) Our Discounted Cash Flow (DCF) analysis suggests BeOne Medicines is undervalued by 64.9%. Track this in your watchlist or portfolio, or discover 48 more high quality undervalued stocks. ONC Discounted Cash Flow as at Mar 2026 Head to the Valuation section of our Company Report for more details on how we arrive at this Fair Value for BeOne Medicines. Approach 2: BeOne Medicines Price vs Earnings For profitable companies, the P/E ratio is a common way to think about what you are paying for each dollar of earnings. This makes it a useful cross check against the DCF work you saw above. In simple terms, higher growth expectations and lower perceived risk usually justify a higher P/E. Slower growth or higher risk tend to line up with a lower, more conservative P/E. So context matters when you look at the headline multiple. BeOne Medicines currently trades on a P/E of 109.77x. That is above the Biotechs industry average P/E of about 20.88x and also higher than the peer group average of 46.25x. Simply Wall St’s Fair Ratio for the stock is 33.59x, which is its proprietary estimate of what a more suitable P/E might be after accounting for factors like earnings growth, profit margins, industry, market cap and company specific risks. Because the Fair Ratio blends these fundamentals, it can give you a more tailored anchor than a simple comparison with industry or peers, which may have very different risk and growth profiles. Comparing the current P/E of 109.77x with the Fair Ratio of 33.59x suggests the shares are trading above that fair multiple estimate. Result: OVERVALUED NasdaqGS:ONC P/E Ratio as at Mar 2026 P/E ratios tell one story, but what if the real opportunity lies elsewhere? Start investing in legacies, not executives. Discover our 18 top founder-led companies. Upgrade Your Decision Making: Choose your BeOne Medicines Narrative Earlier we mentioned that there is an even better way to understand valuation, so let us introduce you to Narratives. With Narratives, you spell out your story for BeOne Medicines, link that story to specific forecasts for revenue, earnings and margins, and the Simply Wall St platform on the Community page turns it into a Fair Value that you can line up against the current share price to help you decide whether to buy, hold or sell. The platform then keeps that Fair Value updating as fresh data like earnings or news arrives. For BeOne Medicines, one investor might lean toward the lower end of analyst expectations with a fair value near US$250, while another might anchor on the higher end around the updated US$507.57 estimate. Narratives let both perspectives sit side by side so you can see exactly which assumptions lead to which valuation. Do you think there's more to the story for BeOne Medicines? Head over to our Community to see what others are saying! NasdaqGS:ONC 1-Year Stock Price Chart  This article by Simply Wall St is general in nature. We provide commentary based on historical data\n    and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your\n    financial situation. We aim to bring you long-term focused analysis driven by fundamental data.\n    Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.\n    Simply Wall St has no position in any stocks mentioned.Valuation is complex, but we're here to simplify it.Discover if BeOne Medicines might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"-1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2619009120","isCrawlerRequest":true}